Volume 85 Issue 35 | p. 23 | Concentrates
Issue Date: August 27, 2007

Enzon Sells Stake in Hepatitis Drug

Department: Business | Collection: Green Chemistry, Economy

Enzon Pharmaceuticals has sold a 25% share of its royalty on Schering-Plough's hepatitis C drug Peg-Intron, to the royalty investment firm Drug Royalty Corp. for $92.5 million. Enzon developed the branch-polyethylene glycol technology that is used, in the case of Peg-Intron, to deliver interferon more efficiently. It stands to receive another $15 million in 2012 if sales of the drug reach a certain level. The Bridgewater, N.J.-based firm plans to use the cash to pay off debt due in 2008.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment